Elicio Therapeutics, Inc.ELTXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank56
3Y CAGR+17.6%
5Y CAGR-8.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+17.6%/yr
vs +6.0%/yr prior
5Y CAGR
-8.1%/yr
Recent acceleration
Acceleration
+11.6pp
Accelerating
Percentile
P56
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $36.87M | -15.8% |
| 2024 | $43.81M | +26.7% |
| 2023 | $34.58M | +52.5% |
| 2022 | $22.68M | -65.8% |
| 2021 | $66.39M | +17.8% |
| 2020 | $56.34M | +44.7% |
| 2019 | $38.94M | +116.5% |
| 2018 | $17.99M | +372.8% |
| 2013 | $3.81M | -5.9% |
| 2012 | $4.04M | - |